Selecta Biosciences, Inc. To Accelerate Program For Novel Dual Action Vaccine For Malaria

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WATERTOWN, Mass.--(BUSINESS WIRE)--First paragraph, second sentence of release should read: The grant supports the research by Selecta for a novel dual action, immune-activating Synthetic Vaccine Particle (SVP) for malaria. (instead of The grant supports the research by Selecta for a novel dual action, immune-activating SVP (SVP) nanoparticle vaccine for malaria.)

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC